Contact
Please use this form to send email to PR contact of this press release:
Immunomic Therapeutics IND Authorized for Phase I Japanese Red Cedar (Sugi) Allergy Vaccine Study
TO:
Please use this form to send email to PR contact of this press release:
Immunomic Therapeutics IND Authorized for Phase I Japanese Red Cedar (Sugi) Allergy Vaccine Study
TO: